An "ultra" PrEP injection just three times a year could be on the way

The new form of the drug is called 'cabotegravir ultra long-acting' (CAB-ULA), with promising results in terms of tolerance and efficacy.

ViiV presented its findings last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) in Denver, Colorado, showcasing improved tolerance and reduced side effects with the new drug formulation.

Read at Queerty